pretty good result. NPAT ($4m+). not bad for a young company....

pretty good result. NPAT ($4m+). not bad for a young company. sales growth and NPAT. no surprise for shareholders who have been closely monitoring for 18+ months. No specific mention of numbers re outlook, except to say they expect momentum to continue, aided by new products and software. gross profit margins look healthy, tight expenditure control paying off, balance sheet looks very healthy. lots of ticks here. all eyes on growth going forward. coming off a low covid base, I'm not expecting a 77% jump, but 25-30%+ would be good.